Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
1. Moderna's Q4 loss exceeded analysts' expectations at $2.91 per share. 2. Expected 2025 revenue of $1.5-$2.5 billion falls short of $3.26 billion consensus. 3. Plans significant cost cuts of $1.1 billion by 2027, focusing on late-stage drugs. 4. Sales in first half of 2025 projected at $200 million due to seasonality. 5. Moderna anticipates multiple drug approvals starting in 2025, including combination vaccines.